The role of adjunctive nephrectomy in patients with metastatic renal cell carcinoma
- PMID: 65479
- DOI: 10.1016/s0022-5347(17)58429-3
The role of adjunctive nephrectomy in patients with metastatic renal cell carcinoma
Abstract
The results of therapy for 78 patients with disseminated renal cell carcinoma are evaluated. Symptoms related to the primary tumor were noted in only 28 per cent of the patients and were not difficult to manage in those patients not undergoing nephrectomy. Adjuctive nephrectomy, therefore, is a more appropriate term than palliative nephrectomy when referring to removal of the primary tumor as part of an aggresive combined therapeutic approach. Of patients receiving an adjunctive nephrectomy those with osseous metastases only had a better 1-year survival rate (36 per cent) than those with metastases to other sites (18 per cent). Complete regression of metastases was noted in 12 per cent of patients treated with medroxyprogesterone acetate and adjunctive nephrectomy. The role of adjunctive nephrectomy combined with embolic infarction, hormonal therapy, chemotherapy and/or immunotherapy is discussed.
Similar articles
-
Indications for and results of nephrectomy for metastatic renal cell carcinoma.Urol Clin North Am. 1980 Oct;7(3):711-7. Urol Clin North Am. 1980. PMID: 6161461
-
The natural history of metastatic renal cell carcinoma: a computer analysis.J Urol. 1978 Aug;120(2):148-52. doi: 10.1016/s0022-5347(17)57082-2. J Urol. 1978. PMID: 78992
-
Osseous metastases secondary to renal cell carcinoma.Urology. 1981 Dec;18(6):556-61. doi: 10.1016/0090-4295(81)90455-6. Urology. 1981. PMID: 7314355
-
Role of surgery in metastatic renal cell carcinoma.Semin Urol. 1989 Aug;7(3):191-4. Semin Urol. 1989. PMID: 2481332 Review.
-
The failure of infarction and/or nephrectomy in stage IV renal cell cancer to influence survival or metastatic regression.Urol Clin North Am. 1987 Nov;14(4):757-62. Urol Clin North Am. 1987. PMID: 3314066 Review.
Cited by
-
Long-term outcomes of the surgical management of renal cell carcinoma.World J Urol. 2006 Aug;24(3):255-66. doi: 10.1007/s00345-006-0055-5. Epub 2006 Feb 15. World J Urol. 2006. PMID: 16479388 Review.
-
Immunotherapeutic strategies in kidney cancer--when TKIs are not enough.Nat Rev Clin Oncol. 2009 Aug;6(8):478-87. doi: 10.1038/nrclinonc.2009.91. Epub 2009 Jun 23. Nat Rev Clin Oncol. 2009. PMID: 19546865 Review.
-
The biology of interleukin-2 efficacy in the treatment of patients with renal cell carcinoma.Med Oncol. 2009;26 Suppl 1:3-12. doi: 10.1007/s12032-008-9162-z. Epub 2009 Jan 16. Med Oncol. 2009. PMID: 19148593 Review.
-
Inflammatory cell infiltrate in a responding metastatic nodule after vaccine-based immunotherapy.Clin Exp Immunol. 1998 Dec;114(3):347-54. doi: 10.1046/j.1365-2249.1998.00731.x. Clin Exp Immunol. 1998. PMID: 9844042 Free PMC article.
-
Treatment of advanced renal cell cancer with recombinant interferon alpha as a single agent and in combination with medroxyprogesterone acetate. A randomized multicenter trial.J Cancer Res Clin Oncol. 1988;114(1):95-100. doi: 10.1007/BF00390492. J Cancer Res Clin Oncol. 1988. PMID: 2965154 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources